Short answer
Lyell Immunopharma Inc (LYEL) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results released March 12, 2026.
Lyell Immunopharma Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results released March 12, 2026
- Full details in Exhibit 99.1 press release: key figures not disclosed in this item text
- LYEL is a clinical-stage immunotherapy company; results likely reflect R&D burn with no product revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lyell Immunopharma Inc 8-K filings
Get the next LYEL 8-K as it lands
Follow LYEL for push alerts, or ask the research agent what this filing means.